Sentences with phrase «received pembrolizumab»

According to an international clinical trial led by Sylvia Adams, MD, associate professor of medicine, breast tumors shrank by more than 30 percent in 12 (23 percent) of 52 patients who received pembrolizumab as first - line therapy, and the disease stabilized in 9 additional patients (17 percent).

Patients in the KEYNOTE trials received pembrolizumab intravenously at doses of 2 mg / kg or 10 mg / kg every three weeks, or 10 mg / kg every two weeks.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

The idea to specifically study this group of patients was based on groundbreaking research Garon published in the New England Journal of Medicine last year, which found that among patients who received pembrolizumab, those with PD - L1 expression on at least 50 percent of their cancer cells showed the longest survival and disease control.

Now, patients with PD - L1 expression on at least half of their cancer cells can receive pembrolizumab prior to standard chemotherapy.

At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE - 045 / EORTC 1325 - MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.

Not exact matches

The FDA also expanded the approval of pembrolizumab to treat the majority of people with NSCLC who had received prior chemotherapy, greatly increasing the patient population that can benefit from the treatment.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

In melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebo.

Pembrolizumab (Keytruda) and nivolumab (Opdivo)-- two checkpoint inhibitors that target the PD - 1 pathway — received FDA approval in 2014 for melanoma that did not respond to prior treatment.

At the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, we presented monotherapy data of nine patients who received G100 with radiation (no pembrolizumab) that showed 100 % DCR rate, with 44 % of the patients achieved a partial response (PR) based on WHO criteria, which requires at least a 50 % tumor reduction to qualify as a PR.

The study will include 330 patients receiving T - VEC plus pembrolizumab and 330 patients taking placebo injections plus pembrolizumab.